DelveInsight Business Research LLP

DelveInsight’s “Microsatellite Stable Colorectal Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Microsatellite Stable Colorectal Cancer (IBS), historical and forecasted epidemiology as well as the Microsatellite Stable Colorectal Cancer (IBS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Microsatellite Stable Colorectal Cancer (IBS) market report provides current treatment practices, emerging drugs, Microsatellite Stable Colorectal Cancer (IBS) market share of the individual therapies, current and forecasted Microsatellite Stable Colorectal Cancer (IBS) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Microsatellite Stable Colorectal Cancer (IBS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Microsatellite Stable Colorectal Cancer (IBS) market.

Key Benefits of the Microsatellite Stable Colorectal Cancer Market

• The report covers the descriptive overview of Microsatellite Stable Colorectal Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies

• Comprehensive insight has been provided into the Microsatellite Stable Colorectal Cancer epidemiology and treatment in the 7MM

• Additionally, an all-inclusive account of both the current and emerging therapies for Microsatellite Stable Colorectal Cancer is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

• A detailed review of the Microsatellite Stable Colorectal Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Microsatellite Stable Colorectal Cancer market

Got queries? Click here to know more about the Microsatellite Stable Colorectal Cancer Market Landscape 

Microsatellite Stable Colorectal Cancer Overview

MSS stands for “Microsatellite Stable tumors have been referred to as “cold” tumors, which means they don’t normally trigger a strong response from the body’s immune system. In terms of the number of tumor genetic mutations, MSS tumors are typically less mutated than MSI-H tumors. In general, non-MSI tumors do not respond to immunotherapies.

Microsatellite Stable Colorectal Cancer Epidemiological Insights:

• The weighted prevalence of MSI-H without genomic studies was estimated to be 14% (95% CI, 10%–19%) across all tumor types and stages. The prevalence was 10% (95% CI, 7%–14%) when four of the five large pan-tumor genomic studies were included (one genomic study was excluded as it did not report the total number of patients or the number of patients with MSI-H). Overall weighted dMMR prevalence was estimated to be 16% (95% CI, 11%–22%) across all tumor types and stages. This estimate remained unchanged (16% (95% CI, 12%–21%)) in the sensitivity analysis, in which two studies (Everett 2014 and Roberts 2013) that possibly screened patients based on their Lynch syndrome status were excluded.

• Country-specific MSI-H prevalence was estimated only in the United States, Korea, and Japan, for which at least 2 publications were included. The weighted prevalence of MSI-H for the United States, Korea, and Japan was estimated at 20% (95% CI, 16%–24%), 9% (95% CI, 6%–12%), and 16% (95% CI, 9%–26%), respectively, across all cancers and stages. dMMR all-stage prevalence for the United States was estimated at 14% (95% CI, 6%–23%) and for Japan was estimated at 20% (95% CI, 0%–63%). Stages 1-2 MSI-H prevalence was 15% (8–23%), while stage 3 and stage 4 prevalence was estimated at 9% (3%–17%) and 3% (1%–7%), respectively.

Microsatellite Stable Colorectal Cancer Market Epidemiological Segmentation

• Microsatellite Stable Colorectal Cancer prevalent population

• Microsatellite Stable Colorectal Cancer incident cases 

• Microsatellite Stable Colorectal Cancer diagnosed cases  

• Microsatellite Stable Colorectal Cancer treated cases 

Microsatellite Stable Colorectal Cancer Market Outlook 

The Microsatellite Stable Colorectal Cancer market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Microsatellite Stable Colorectal Cancer market trends by analyzing the impact of current Microsatellite Stable Colorectal Cancer therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Microsatellite Stable Colorectal Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Microsatellite Stable Colorectal Cancer market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Microsatellite Stable Colorectal Cancer market in 7MM is expected to witness a major change in the study period 2019-2032.

 Learn more by requesting for sample @ Microsatellite Stable Colorectal Cancer Market Landscape

 Microsatellite Stable Colorectal Cancer Market Key Companies  

• Merck 

• MedImmune Inc 

• Takeda 

• Redx Pharma 

• Pfizer 

• And many others 

 Microsatellite Stable Colorectal Cancer Therapies 

• Grapiprant

• Pembrolizumab

• Durvalumab 

• Monalizumab

Table of Contents

1. Key Insights 

2. Report Introduction 

3. Executive Summary of Microsatellite Stable Colorectal Cancer Market 

4. Disease Background and Overview

5. Epidemiology and patient population

6. The United States 

7. EU 5

8. Microsatellite Stable Colorectal Cancer  Market  Emerging Therapies

9. Microsatellite Stable Colorectal Cancer  Market Outlook

10.  Market Access and Reimbursement of Therapies

11.  Appendix

12.  Microsatellite Stable Colorectal Cancer   Market  Report Methodology

13.  DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services